Integrated Bioinformatic Analysis of SARS-CoV-2 Infection Related Genes ACE2, BSG and TMPRSS2 in Aerodigestive Cancers

References

• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280 e278. doi:10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Kong Q, Xiang Z, Wu Y, Gu Y, Guo J, Geng F. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection. Mol Cancer. 2020;19(1):80. doi:10.1186/s12943-020-01209-2
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782. doi:10.1001/jama.2020.12839
   PubMed Web of Science ®Google Scholar
• Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020.
   Google Scholar
• Qiao J, Li W, Bao J, et al. The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues. Biochem Biophys Res Commun. 2020;533:867–871. doi:10.1016/j.bbrc.2020.09.042
   PubMed Web of Science ®Google Scholar
• Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun. 2017;85:117–125. doi:10.1016/j.jaut.2017.07.010
   PubMed Web of Science ®Google Scholar
• Zhang H, Quek K, Chen R, Chen J, Chen B. Expression of the SAR2-Cov-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer. J Cancer. 2020;11(18):5289–5292. doi:10.7150/jca.49462
   PubMed Web of Science ®Google Scholar
• Ilikci Sagkan R, Akin-Bali DF. Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in lung cancer. J Med Virol. 2020;92:2637–2647. doi:10.1002/jmv.26107
   PubMed Web of Science ®Google Scholar
• Katopodis P, Anikin V, Randeva HS, et al. Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19. Int J Oncol. 2020;57(2):533–539. doi:10.3892/ijo.2020.5071
   PubMed Web of Science ®Google Scholar
• Huang X, He C, Hua X, et al. Bioinformatic analysis of correlation between immune infiltration and COVID-19 in cancer patients. Int J Biol Sci. 2020;16(13):2464–2476. doi:10.7150/ijbs.48639
   PubMed Web of Science ®Google Scholar
• Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:10.1016/S1470-2045(20)30096-6
   PubMed Web of Science ®Google Scholar
• Tian Y, Qiu X, Wang C, et al. Cancer associates with risk and severe events of COVID-19: a systematic review and meta-analysis. Int J Cancer. 2020;148:363–374. doi:10.1002/ijc.33213
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lionakis MS, Kontoyiannis DP. Are all patients with cancer at heightened risk for severe Coronavirus Disease 2019 (COVID-19)? Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1079
   Google Scholar
• Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309–1316. doi:10.1016/S1470-2045(20)30442-3
   PubMed Web of Science ®Google Scholar
• Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. Science (New York, NY). 2020;369(6499):50–54. doi:10.1126/science.abc1669
   Google Scholar
• Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002;532(1–2):107–110. doi:10.1016/S0014-5793(02)03640-2
   PubMed Web of Science ®Google Scholar
• Liu YL, Ren J, Yuan JP, et al. Postoperative onset and detection of SARS-CoV-2 in surgically resected specimens from gastrointestinal cancer patients with pre/asymptomatic COVID-19. Ann Surg. 2020;272(6):e321–e328. doi:10.1097/SLA.0000000000004362
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–w560. doi:10.1093/nar/gkz430
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–607. doi:10.1038/nature11003
   PubMed Web of Science ®Google Scholar
• Cao T, Pan W, Sun X, Shen H. Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis. J Ovarian Res. 2019;12(1):101. doi:10.1186/s13048-019-0575-4
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Huang X, He C, Lin G, et al. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun. 2020;524(4):1064–1071. doi:10.1016/j.bbrc.2020.02.042
   PubMed Web of Science ®Google Scholar
• Wang T, Ruan S, Zhao X, et al. OncoVar: an integrated database and analysis platform for oncogenic driver variants in cancers. Nucleic Acids Res. 2021;49(D1):D1289–d1301. doi:10.1093/nar/gkaa1033
   PubMed Web of Science ®Google Scholar
• Sheffer M, Bacolod MD, Zuk O, et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A. 2009;106(17):7131–7136. doi:10.1073/pnas.0902232106
   PubMed Web of Science ®Google Scholar
• Pan JH, Zhou H, Cooper L, et al. LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. Front Immunol. 2019;10:6. doi:10.3389/fimmu.2019.00006
   PubMed Web of Science ®Google Scholar
• Matusiak M, Schürch CM. Expression of SARS-CoV-2 entry receptors in the respiratory tract of healthy individuals, smokers and asthmatics. Respir Res. 2020;21(1):252. doi:10.1186/s12931-020-01521-x
   PubMed Web of Science ®Google Scholar
• Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet (London, England). 2020;395(10241):1919–1926. doi:10.1016/S0140-6736(20)31173-9
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England). 2020;395(10241):1907–1918. doi:10.1016/S0140-6736(20)31187-9
   PubMed Web of Science ®Google Scholar
• Womersley K, Ripullone K, Peters SA, Woodward M. Covid-19: male disadvantage highlights the importance of sex disaggregated data. BMJ. 2020;370:m2870. doi:10.1136/bmj.m2870
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315–320. doi:10.1038/s41586-020-2700-3
   PubMed Web of Science ®Google Scholar
• Kopel J, Perisetti A, Roghani A, Aziz M, Gajendran M, Goyal H. Racial and gender-based differences in COVID-19. Front Public Health. 2020;8:418. doi:10.3389/fpubh.2020.00418
   PubMed Web of Science ®Google Scholar
• Bernardi S, Zennaro C, Palmisano S, et al. Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. JRAAS. 2012;13(1):202–209. doi:10.1177/1470320311426023
   Google Scholar
• Aran D, Lasry A, Zinger A, et al. Widespread parainflammation in human cancer. Genome Biol. 2016;17(1):145. doi:10.1186/s13059-016-0995-z
   PubMedGoogle Scholar
• Ying L, Yan F, Meng Q, et al. Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry. J Transl Med. 2017;15(1):206. doi:10.1186/s12967-017-1311-8
   PubMedGoogle Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e1039. doi:10.1016/j.cell.2020.04.026
   PubMed Web of Science ®Google Scholar
• Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. doi:10.1158/2159-8290.CD-20-0422
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer. 2020;126(17):4023–4031. doi:10.1002/cncr.33042
   PubMed Web of Science ®Google Scholar
• Wang B, Huang Y. Which type of cancer patients are more susceptible to the SARS-COX-2: evidence from a meta-analysis and bioinformatics analysis. Crit Rev Oncol Hematol. 2020;153:103032. doi:10.1016/j.critrevonc.2020.103032
   PubMed Web of Science ®Google Scholar
• Stewart CA, Gay CM, Ramkumar K, et al. SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models. bioRxiv. 2020. doi:10.1101/2020.05.28.122291
   Google Scholar
• Zhao B, Ni C, Gao R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020;1–5.
   PubMed Web of Science ®Google Scholar
• Sharma A, Garcia G, Wang Y, et al. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Rep Med. 2020;1(4):100052. doi:10.1016/j.xcrm.2020.100052
   PubMedGoogle Scholar